Edmond De Rothschild (italia) Sgr Spa buys $8,293,936 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Edmond De Rothschild (italia) Sgr Spa scooped up 1,422 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 184,146 shares of Abbott Laboratories which is valued at $8,293,936.Abbott Laboratories makes up approximately 11.06% of Edmond De Rothschild (italia) Sgr Spa’s portfolio.

Other Hedge Funds, Including , M&r Capital Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 2,727 additional shares and now holds a total of 26,151 shares of Abbott Laboratories which is valued at $1,177,841. Abbott Laboratories makes up approx 0.30% of M&r Capital Management Inc’s portfolio.Janney Capital Management reduced its stake in ABT by selling 200 shares or 3.72% in the most recent quarter. The Hedge Fund company now holds 5,177 shares of ABT which is valued at $234,311. Abbott Laboratories makes up approx 0.01% of Janney Capital Management’s portfolio.Mcqueen Ball Associates boosted its stake in ABT in the latest quarter, The investment management firm added 390 additional shares and now holds a total of 46,740 shares of Abbott Laboratories which is valued at $2,017,766. Abbott Laboratories makes up approx 1.39% of Mcqueen Ball Associates’s portfolio.Capital Advantage boosted its stake in ABT in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 5,071 shares of Abbott Laboratories which is valued at $213,438. Abbott Laboratories makes up approx 0.07% of Capital Advantage’s portfolio.Somerset Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 8,533 additional shares and now holds a total of 29,342 shares of Abbott Laboratories which is valued at $1,231,484. Abbott Laboratories makes up approx 0.74% of Somerset Trust Co’s portfolio.

Abbott Laboratories closed down -0.12 points or -0.27% at $44.24 with 94,39,877 shares getting traded on Friday. Post opening the session at $44.17, the shares hit an intraday low of $43.645 and an intraday high of $44.31 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *